Patients who received either dose of abelacimab had a significantly lower risk for the primary outcome than those who received rivaroxaban, both among those aged 75 years or older (90 mg: hazard ratio ...
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results ...
Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results